Filing Details

Accession Number:
0000899243-20-017315
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-19 21:31:43
Reporting Period:
2020-06-17
Accepted Time:
2020-06-19 21:31:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1629137 Global Blood Therapeutics Inc. GBT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1574579 Dawn Svoronos C/o Global Blood Therapeutics, Inc.
181 Oyster Point Blvd.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-17 4,800 $0.00 4,800 No 4 M Direct
Common Stock Disposition 2020-06-19 1,663 $63.69 3,137 No 4 S Direct
Common Stock Disposition 2020-06-19 881 $64.42 2,256 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2020-06-17 4,800 $0.00 4,800 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2020-06-17 5,247 $0.00 5,247 $64.75
Common Stock Restricted Stock Units Acquisiton 2020-06-17 3,037 $0.00 3,037 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
5,247 2030-06-16 No 4 A Direct
3,037 No 4 A Direct
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. Represents number of shares of Issuer's Common Stock sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2020, for the Reporting Person's taxes in connection with the vesting of 4,800 shares of Common Stock underlying the Reporting Person's RSUs.
  3. Represents weighted average sales price. The shares were sold at prices ranging from $63.23 to $63.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. Represents weighted average sales price. The shares were sold at prices ranging from $64.24 to $64.60. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  5. The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
  6. The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
  7. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).